Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) have received a consensus rating of “Hold” from the five research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $9.75.
ALPN has been the subject of several recent analyst reports. Zacks Investment Research upgraded Alpine Immune Sciences from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a report on Tuesday, December 26th. ValuEngine upgraded Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th.
Shares of Alpine Immune Sciences (NASDAQ:ALPN) traded up $0.02 during trading on Friday, hitting $9.04. The company’s stock had a trading volume of 5,400 shares, compared to its average volume of 12,870. Alpine Immune Sciences has a 12 month low of $7.20 and a 12 month high of $14.52. The company has a market capitalization of $125.22, a P/E ratio of -0.96 and a beta of 0.17. The company has a quick ratio of 32.38, a current ratio of 32.38 and a debt-to-equity ratio of 0.05.
Several hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its position in shares of Alpine Immune Sciences by 29.9% during the fourth quarter. Renaissance Technologies LLC now owns 67,500 shares of the biotechnology company’s stock worth $756,000 after buying an additional 15,521 shares during the period. Victory Capital Management Inc. boosted its position in shares of Alpine Immune Sciences by 29.7% during the fourth quarter. Victory Capital Management Inc. now owns 51,551 shares of the biotechnology company’s stock worth $577,000 after buying an additional 11,799 shares during the period. Millennium Management LLC acquired a new position in shares of Alpine Immune Sciences during the fourth quarter worth about $205,000. Sowell Financial Services LLC acquired a new position in shares of Alpine Immune Sciences during the third quarter worth about $162,000. Finally, Wells Fargo & Company MN acquired a new position in shares of Alpine Immune Sciences during the fourth quarter worth about $118,000. 56.62% of the stock is owned by institutional investors.
Alpine Immune Sciences Company Profile
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.